Figure 2.

Protective efficacy of pLASV-GPC vaccine against lethal viral challenge in NHPs. pLASV-GPC DNA-immunized and non-immunized control NHPs (n of 6 each) were challenged with a lethal dose of LASV at four weeks post-final immunization. NHPs were monitored daily for survival (a) and clinical signs of disease (b).